Overview Dividends

(STZ) Constellation Brands - Ratings and Ratios

Exchange: NYSE • Country: United States • Currency: USD • Type: Common Stock • ISIN: US21036P1084

Beer, Wine, Spirits

STZ EPS (Earnings per Share)

EPS Growth (3Y CAGR): 9.48%
EPS Trend (3Y Correlation): 41.0%

STZ Revenue

Revenue Growth (3Y CAGR): 0.66%
Revenue Trend (3Y Correlation): 13.9%

Risk via 10d forecast
Volatility	28.0%
Value at Risk 5%th	43.3%

Reward
Sharpe Ratio	-1.73
Alpha Jensen	-54.10

Character
Hurst Exponent	0.508
Beta	0.660

Drawdowns 3y
Max DD	51.28%
Mean DD	16.81%

Description: STZ Constellation Brands October 14, 2025

Constellation Brands Inc. (NYSE: STZ) is a diversified alcoholic-beverage company that produces, imports, markets, and distributes beer, wine, and spirits across the United States, Canada, Mexico, New Zealand, and Italy. Its beer portfolio includes Corona (Extra, Light, Hard Seltzer, Non-Alcoholic, etc.) and Modelo brands, while its wine lineup features Robert Mondavi, Kim Crawford, Meiomi, and The Prisoner, and its spirits business holds Casa Noble, High West, and SVEDKA among others. The firm sells through wholesale distributors, retailers, on-premise venues, and state alcohol-control agencies.

Key recent metrics (FY 2023) show revenue of approximately $9.6 billion, adjusted EPS of $2.70, and free cash flow of $1.2 billion, with net debt around $14 billion. The company’s growth is driven by premium-segment expansion (e.g., higher-margin craft and super-premium beers), the continued popularity of ready-to-drink seltzers, and favorable pricing power amid modest discretionary-spending resilience. However, exposure to excise-tax policy changes in the U.S. and currency fluctuations in its international markets adds material risk to earnings forecasts.

For a deeper, data-rich analysis of STZ’s valuation and risk profile, you may find ValueRay’s research tools useful as a next step in your due-diligence process.

STZ Stock Overview

Market Cap in USD	23,000m
Sub-Industry	Distillers & Vintners
IPO / Inception	1987-01-01
Return 12m vs S&P 500	-50.4%
Analyst Rating	3.96 of 5

STZ Dividends

Dividend Yield	3.09%
Yield on Cost 5y	2.19%
Yield CAGR 5y	6.92%
Payout Consistency	100.0%
Payout Ratio	32.0%

STZ Growth Ratios

CAGR	-17.12%
CAGR/Max DD Calmar Ratio	-0.33
CAGR/Mean DD Pain Ratio	-1.02
Current Volume	2920.7k
Average Volume	2226k

Piotroski VR‑10 (Strict, 0-10) 6.5

Net Income (1.22b TTM) > 0 and > 6% of Revenue (6% = 577.4m TTM)

FCFTA 0.09 (>2.0%) and ΔFCFTA 1.52pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)

NWC/Revenue 2.28% (prev 7.19%; Δ -4.91pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)

CFO/TA 0.13 (>3.0%) and CFO 2.77b > Net Income 1.22b (YES >=105%, WARN >=100%)

Net Debt (9.97b) to EBITDA (2.56b) ratio: 3.90 <= 3.0 (WARN <= 3.5)

Current Ratio 1.08 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)

Outstanding Shares last Quarter (175.9m) change vs 12m ago -3.30% (target <= -2.0% for YES)

Gross Margin 51.43% (prev 50.50%; Δ 0.94pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)

Asset Turnover 43.25% (prev 44.15%; Δ -0.90pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)

Interest Coverage Ratio 5.40 (EBITDA TTM 2.56b / Interest Expense TTM 392.8m) >= 6 (WARN >= 3)

Altman Z'' 3.73

(A) 0.01 = (Total Current Assets 2.88b - Total Current Liabilities 2.66b) / Total Assets 21.42b

(B) 0.62 = Retained Earnings (Balance) 13.23b / Total Assets 21.42b

(D) 0.96 = Book Value of Equity 13.14b / Total Liabilities 13.63b

Total Rating: 3.73 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 63.92

1. Piotroski 6.50pt = 1.50

2. FCF Yield 5.61% = 2.80

3. FCF Margin 19.20% = 4.80

4. Debt/Equity 1.34 = 1.67

5. Debt/Ebitda 3.90 = -2.49

6. ROIC - WACC (= 0.93)% = 1.17

7. RoE 16.60% = 1.38

8. Rev. Trend 13.95% = 1.05

9. EPS Trend 40.97% = 2.05

What is the price of STZ shares?

As of November 13, 2025, the stock is trading at USD 131.81 with a total of 2,920,667 shares traded.
Over the past week, the price has changed by +2.04%, over one month by -6.08%, over three months by -21.26% and over the past year by -42.78%.

Is Constellation Brands a good stock to buy?

Neither. Based on ValueRay´s Fundamental Analyses, Constellation Brands is currently (November 2025) neither a good nor a bad stock to buy. It has a ValueRay Fundamental Rating of 63.92 and therefor a neutral outlook according to the companies health.
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of STZ is around 115.92 USD . This means that STZ is currently overvalued and has a potential downside of -12.06%.

Is STZ a buy, sell or hold?

Constellation Brands has received a consensus analysts rating of 3.96. Therefore, it is recommended to buy STZ.

Strong Buy: 9
Buy: 7
Hold: 10
Sell: 0
Strong Sell: 0

What are the forecasts/targets for the STZ price?

Issuer	Target	Up/Down from current
Wallstreet Target Price	172.6	31%
Analysts Target Price	172.6	31%
ValueRay Target Price	126.4	-4.1%

STZ Fundamental Data Overview November 03, 2025

Market Cap USD = 23.00b (23.00b USD * 1.0 USD.USD)
P/E Trailing = 19.1237
P/E Forward = 12.0192
P/S = 2.3899
P/B = 3.4094
P/EG = 1.5758
Beta = 0.66
Revenue TTM = 9.62b USD
EBIT TTM = 2.12b USD
EBITDA TTM = 2.56b USD
Long Term Debt = 9.29b USD (from longTermDebt, last fiscal year)
Short Term Debt = 252.5m USD (from shortTermDebt, last quarter)
Debt = 10.04b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 9.97b USD (from netDebt column, last quarter)
Enterprise Value = 32.97b USD (23.00b + Debt 10.04b - CCE 72.0m)
Interest Coverage Ratio = 5.40 (Ebit TTM 2.12b / Interest Expense TTM 392.8m)
FCF Yield = 5.61% (FCF TTM 1.85b / Enterprise Value 32.97b)
FCF Margin = 19.20% (FCF TTM 1.85b / Revenue TTM 9.62b)
Net Margin = 12.71% (Net Income TTM 1.22b / Revenue TTM 9.62b)
Gross Margin = 51.43% ((Revenue TTM 9.62b - Cost of Revenue TTM 4.67b) / Revenue TTM)
Gross Margin QoQ = 52.80% (prev 50.77%)
Tobins Q-Ratio = 1.54 (Enterprise Value 32.97b / Total Assets 21.42b)
Interest Expense / Debt = 0.87% (Interest Expense 87.6m / Debt 10.04b)
Taxrate = 37.91% (296.8m / 782.9m)
NOPAT = 1.32b (EBIT 2.12b * (1 - 37.91%))
Current Ratio = 1.08 (Total Current Assets 2.88b / Total Current Liabilities 2.66b)
Debt / Equity = 1.34 (Debt 10.04b / totalStockholderEquity, last quarter 7.50b)
Debt / EBITDA = 3.90 (Net Debt 9.97b / EBITDA 2.56b)
Debt / FCF = 5.39 (Net Debt 9.97b / FCF TTM 1.85b)
Total Stockholder Equity = 7.37b (last 4 quarters mean from totalStockholderEquity)
RoA = 5.71% (Net Income 1.22b / Total Assets 21.42b)
RoE = 16.60% (Net Income TTM 1.22b / Total Stockholder Equity 7.37b)
RoCE = 12.74% (EBIT 2.12b / Capital Employed (Equity 7.37b + L.T.Debt 9.29b))
RoIC = 6.98% (NOPAT 1.32b / Invested Capital 18.87b)
WACC = 6.05% (E(23.00b)/V(33.04b) * Re(8.45%) + D(10.04b)/V(33.04b) * Rd(0.87%) * (1-Tc(0.38)))
Discount Rate = 8.45% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -100.0 | Cagr: -2.26%
[DCF Debug] Terminal Value 77.45% ; FCFE base≈1.76b ; Y1≈1.84b ; Y5≈2.12b
Fair Price DCF = 196.9 (DCF Value 34.47b / Shares Outstanding 175.0m; 5y FCF grow 4.45% → 3.0% )
EPS Correlation: 40.97 | EPS CAGR: 9.48% | SUE: 1.17 | # QB: 1
Revenue Correlation: 13.95 | Revenue CAGR: 0.66% | SUE: 0.54 | # QB: 0

Additional Sources for STZ Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle